Laman UtamaPRE • NASDAQ
add
Prenetics Global Ltd
$4.42
Selepas Waktu Dagangan:(5.20%)+0.23
$4.65
Tutup: 22 Nov, 8:00:00 PTG GMT-5 · USD · NASDAQ · Penafian
Tutup sebelumnya
$4.61
Julat hari
$4.42 - $4.42
Julat tahun
$2.85 - $7.84
Permodalan pasaran
54.00J USD
Bilangan Purata
11.72K
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Berita pasaran
GS
1.12%
0.35%
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(USD) | Jun 2024info | Perubahan T/T |
---|---|---|
Hasil | 5.94J | 4.32% |
Perbelanjaan pengendalian | 14.38J | 0.52% |
Pendapatan bersih | -10.72J | 50.83% |
Margin untung bersih | -180.46 | 52.87% |
Pendapatan bagi setiap syer | — | — |
EBITDA | -9.51J | 13.59% |
Kadar cukai berkesan | 0.79% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
(USD) | Jun 2024info | Perubahan T/T |
---|---|---|
Pelaburan tunai dan jangka pendek | 63.89J | -67.46% |
Jumlah aset | 233.31J | -16.93% |
Jumlah liabiliti | 42.30J | -30.22% |
Jumlah ekuiti | 191.00J | — |
Syer tertunggak | 12.22J | — |
Harga kepada buku | 0.30 | — |
Pulangan pada aset | -11.12% | — |
Pulangan pada modal | -13.33% | — |
Aliran Tunai
Perubahan bersih dalam tunai
(USD) | Jun 2024info | Perubahan T/T |
---|---|---|
Pendapatan bersih | -10.72J | 50.83% |
Tunai daripada operasi | — | — |
Tunai daripada pelaburan | — | — |
Tunai daripada pembiayaan | — | — |
Perubahan bersih dalam tunai | — | — |
Aliran tunai bebas | — | — |
Perihal
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer.
Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions.
The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
Diasaskan
2014
Tapak web
Pekerja
322